NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks rose 0.5% with the Danish ones rising 8%. Most notably, Biosergen rose 145% with very strong momentum throughout the week. Further, Virogates entered into a distribution agreement, Genmab beat sales expectations, Acarix secured yet another order, and Cessatech announced recruitment of 75 patients in their Paediatric Study 0202.
Only 12 of the 22 Danish biotech companies had a positive share price development in the past week and 11 companies have had a positive share price performance year-to-date Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance. Five Danish healthcare stocks with +100% YTD return.
Danish company news
Acarix Secures Expansion Order from Existing CADScor System Customer (Link)
No news the past week
No news the past week
Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202 (Link)
No news the past week
No news the past week
No news the past week
No news the past week
ExpreS2ion and Serum Institute of India have entered in a term sheet regarding proposed development and commercialization of novel malaria vaccines (Link)
No news the past week
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 (Link)
Jyske Bank lowered their price target from DKK 2,600 to DKK 2,400, and UBS to DKK 2,700 from DKK 2,850.
No news the past week
The decision to issue new shares and conduct share buyback, as well as the sale of shares in connection with the long-term incentive program for 2023 (Link)
No news the past week
PILA PHARMA INFORMS OF OPTIMIZATION CHANGES TO TRIAL PLAN (Link)
Saniona Ion Channel Research Collaboration with Boehringer Ingelheim Reaches Milestone (Link)
No news the past week
No news the past week
ViroGates announces a distribution agreement with suPAR Health and a directed issue of shares to suPAR Remedy LLC (Link)
Bank of America initiated a price target of DKK 1,100, while the current stock price is DKK 805
No news the past week
No news the past week
Share price development – Danish stocks
On average, the Danish biotech and healthcare stocks delivered a return of 8% driven by Biosergen with a 145% return. Biosergen delivered very strong momentum throughout the week with daily double-digit increases although the company did not report any news. ViroGates entered a distribution agreement with suPAR Health in the U.S. as well as a directed issue of MDKK 8.2 with suPAR Remedy at a 10% premium. Genmab beat expectations of Darzalex sales by a couple of percentages, while Acarix got yet another new order. Moreover, Cessatech announced the recruitment of 75 patients in their Paediatric Study 0202 being halfway to 150 patients. Finally, Evaxion entered into a term sheet regarding the development of malaria vaccines together with the Serum Institute of India.
Gubra continues to be the best-performing stock year-to-date with a return of 242%. Pila Pharma, Zealand Pharma, Cessatech, and Y-mAbs Therapeutic have also generated returns of over 100% in 2024.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) rose 0.5% to 66,43. The index has had a strong performance since the beginning of October last year and it has now not only surpassed the KPNGX index but it has also joined the larger indices regarding performance. In the past 12 months, the KPHC index has thus had higher volatility but is now among the same performance as C25 and S30 – far better than the other Nordic growth exchange stocks.
The Nordic healthcare stocks (KPHC) vs. C25, S30, and KPNGX the past year
The top three best-performing stocks in the past week
Biosergen (145%) specializes in the research and development of various drugs. The product portfolio includes, for example, the company’s product BSG005, an antifungal drug in the clinical phase. In addition to the main business, the company also offers service and related ancillary services. Operations are conducted in Norway.
Alteco Medical AB (75%) is active in medical technology and provides an extracorporeal blood purification product that removes endotoxin (lipopolysaccharide, LPS) from the patient’s bloodstream. The product is used as an adjunctive therapy in sepsis to treat endotoxemia (high levels of endotoxin). This can help to stabilize the patient in various acute situations. Endotoxemia is common in sepsis, which is a life-threatening condition and one of the most common causes of death in modern intensive care.
PharmaLundensis AB (58%) specializes in the development of medical devices. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical data and potential fertilization.
Resources: Refinitiv Eikon, Cision, Nordnet & company websites
